News from ardelyx A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 08, 2018, 04:05 ET Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights

Ardelyx, Inc. (NASDAQ: ARDX), today reported business highlights and financial results for the first quarter ended March 31, 2018. "The first quarter ...


Feb 12, 2018, 06:30 ET Ardelyx Announces Departure of Chief Scientific Officer

Ardelyx, Inc. (NASDAQ: ARDX) today announced that Jeremy Caldwell, Ph.D., chief scientific officer, will be leaving the company, effective February...


Feb 08, 2018, 06:30 ET Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference

Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at ...


Jan 03, 2018, 06:35 ET Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference

Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present a company overview at the ...


Jan 03, 2018, 06:30 ET Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C

Ardelyx, Inc. (NASDAQ: ARDX) today announced that the company successfully completed the safety extension portion of its Phase 3 T3MPO program,...


Dec 11, 2017, 05:00 ET Ardelyx Announces License Agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China

Ardelyx, Inc. (NASDAQ: ARDX) today announced that the company has entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial...


Nov 28, 2017, 01:00 ET Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan

Ardelyx, Inc. (NASDAQ: ARDX) and Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, "Kyowa Hakko Kirin"), today announced that they have entered into a...


Nov 21, 2017, 05:30 ET Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline

Ardelyx, Inc. (NASDAQ: ARDX) today provided an update on the development of its cardiorenal pipeline. The company's second registration study for...


Nov 07, 2017, 05:30 ET Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress

Ardelyx, Inc. (NASDAQ: ARDX), today provided an update on its clinical programs and reported financial results for the third quarter ended September...


Oct 16, 2017, 08:01 ET Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling

Ardelyx, Inc. (NASDAQ: ARDX) today reported that data from preclinical studies have shown that tenapanor works to reduce abdominal pain caused by...


Oct 11, 2017, 16:02 ET Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018

Ardelyx, Inc. (NASDAQ: ARDX) today reported positive results from T3MPO-2, its second Phase 3 study of tenapanor for irritable bowel syndrome with...


Aug 09, 2017, 06:30 ET Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results

Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) ...


Aug 02, 2017, 06:30 ET Ardelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference

Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) ...


May 12, 2017, 06:30 ET Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C

Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) ...


May 05, 2017, 06:30 ET Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress

Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) ...


Apr 18, 2017, 06:30 ET Ardelyx To Present at Upcoming Spring Medical Meetings

Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) ...


Feb 27, 2017, 15:05 ET Ardelyx Announces Presentation at Cowen and Company 37th Annual Healthcare Conference

Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) ...


Feb 17, 2017, 15:05 ET Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results

Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardiorenal and gastrointestinal (GI) diseases, today reported...


Feb 15, 2017, 05:30 ET Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease

Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI)...


Jan 03, 2017, 06:35 ET Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia

Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage company focused on enhancing the treatment of patients with gastrointestinal and cardiorenal diseases, ...


Jan 03, 2017, 06:30 ET Ardelyx Announces Presentation at J.P. Morgan 35th Annual Healthcare Conference

Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage company focused on enhancing the treatment of patients with gastrointestinal and cardiorenal diseases, ...


Nov 07, 2016, 04:01 ET Ardelyx Reports Third Quarter 2016 Financial Results and Recent Progress

Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today reported an...


Oct 31, 2016, 04:30 ET Ardelyx to Announce Third Quarter 2016 Financial Results on November 7, 2016

Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that...


Oct 24, 2016, 07:00 ET Ardelyx Strengthens Executive Leadership with the Appointment of Reginald Seeto, MBBS, as Chief Operating Officer

Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that...


Oct 19, 2016, 07:00 ET Ardelyx Announces the Presentation of Positive Global Endpoint Findings from Phase 2b Trial of Tenapanor in Patients with IBS-C at ACG Annual Meeting

Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced the...